Matinas BioPharma Holdings Inc (MTNB) - Total Assets
Based on the latest financial reports, Matinas BioPharma Holdings Inc (MTNB) holds total assets worth $5.87 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Matinas BioPharma Holdings Inc - Total Assets Trend (2012–2025)
This chart illustrates how Matinas BioPharma Holdings Inc's total assets have evolved over time, based on quarterly financial data. Also see Matinas BioPharma Holdings Inc market cap and net worth for the company's overall valuation and market capitalisation.
Matinas BioPharma Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Matinas BioPharma Holdings Inc's total assets of $5.87 Million consist of 56.5% current assets and 43.5% non-current assets. Review MTNB total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.26 Million | 31.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Matinas BioPharma Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Matinas BioPharma Holdings Inc (MTNB) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Matinas BioPharma Holdings Inc's current assets represent 56.5% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 55.5% of total assets in 2025, down from 100.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 31.4% of total assets.
Matinas BioPharma Holdings Inc Competitors by Total Assets
Key competitors of Matinas BioPharma Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Matinas BioPharma Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.32 | 3.35 | 16.97 |
| Quick Ratio | 1.32 | 3.35 | 16.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $689.00K | $5.29 Million | $57.35 Million |
Matinas BioPharma Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Matinas BioPharma Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | -43.0% |
| Total Assets | $7.21 Million |
| Market Capitalization | $4.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Matinas BioPharma Holdings Inc's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Matinas BioPharma Holdings Inc's assets decreased by 43.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Matinas BioPharma Holdings Inc (2012–2025)
The table below shows the annual total assets of Matinas BioPharma Holdings Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.21 Million | -42.98% |
| 2024-12-31 | $12.64 Million | -49.65% |
| 2023-12-31 | $25.10 Million | -68.17% |
| 2022-12-31 | $78.87 Million | +28.60% |
| 2021-12-31 | $61.33 Million | -13.59% |
| 2020-12-31 | $70.97 Million | +76.36% |
| 2019-12-31 | $40.24 Million | +101.77% |
| 2018-12-31 | $19.94 Million | +38.27% |
| 2017-12-31 | $14.42 Million | +46.94% |
| 2016-12-31 | $9.82 Million | +16.78% |
| 2015-12-31 | $8.41 Million | +150.07% |
| 2014-12-31 | $3.36 Million | -70.34% |
| 2013-12-31 | $11.33 Million | +2570.76% |
| 2012-12-31 | $424.36K | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more